UK Markets closed


LSE - LSE Delayed price. Currency in GBp
Add to watchlist
109.25-0.75 (-0.68%)
At close: 5:39PM BST
Sign in to post a message.
  • E
    More good news for business expansion.
    Contract secured for bespoke assay development 28/7/21
    ANGLE plc has agreed a pharma services contract with another new customer for its recently established pharma services business. ANGLE will develop immunofluorescence (IF) assays using its Parsortix® system to detect two specific protein markers expressed by circulating tumour cells (CTCs) and implicated in DNA damage repair (DDR). The new customer is a well-funded clinical stage development company with established commercialisation agreements with multiple global pharma companies. ........
    The first phase of work agreed covers the initial assay development and validation contract generating revenues of c. US$ 400,000 over a 12 month period.................
    Once developed, the new assays will remain in the ownership of ANGLE and be added to ANGLE's menu of pre-developed tests that can be offered to other pharma customers. .......
    ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers.

    Assuming the FDA approval comes through this year, this stock will surely fly.
  • S
    FDA approval for Angle’s liquid biopsy will send this rocketing. Buying before the announcement. GLA and please do your own research
  • g
    if you're not in this already you haven't been paying attention.
    will change cancer diagnosis as we know it.
    on a global scale.
    1 major pharma already on board confident of approval